Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells
Sign Up to like & getrecommendations! Published in 2021 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.13090
Abstract: Sunitinib (Sun), a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, is the standard first‐line treatment against advanced clear cell renal cell carcinoma (RCC), but resistance to therapy is inevitable. Reactive oxygen species production… read more here.
Keywords: sirt5; dysregulation sirt5; sirt5 idh2; sun ... See more keywords